Lepu Medical (300003.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 7...
According to the Zhitong Finance App, Lepu Healthcare (300003.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 7.98 billion yuan, achieved net profit attributable to shareholders of listed companies of 1,258 billion yuan, and realized net profit of 1,123 billion yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss, with basic earnings per share of 0.677 yuan. It is proposed to distribute a cash dividend of 3.3141 yuan (tax included) for every 10 shares to all shareholders.
The report shows that sales of emergency rapid test kits and PCR instruments in the in vitro diagnosis business contributed greatly to revenue during the same period last year. After excluding in vitro diagnosis business, the segment's revenue increased 6.70% year on year. Among them: coronary implant intervention business revenue increased 2.9% year on year; structural heart disease business revenue increased 29.08% year on year; surgical anesthesia business revenue increased 9.37% year on year; in vitro diagnosis business revenue decreased 77.79% year on year.